261633-71-0

Usage

Uses

2,3-Dihydro-1,4-benzodioxin-5-ylmethylamine, HCl

InChI:InChI=1/C9H11NO2.ClH/c10-6-7-2-1-3-8-9(7)12-5-4-11-8;/h1-3H,4-6,10H2;1H

Upstream product

• 33632-34-7 5-methyl-2,3-dihydrobenzo[b][1,4]dioxine 
• 488-17-5 3-methylbenzene-1,2-diol 
• 214894-89-0 5-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine 
• 214894-98-1 2-(2,3-dihydro-benzo[1,4]dioxin-5-ylmethyl)-isoindole-1,3-dione 

Downstream Products

• 1051929-86-2 tert-butyl 2-((tert-butoxycarbonyl)(methyl)amino)ethyl(3-(5-((2,3-dihydrobenzo[b][1,4]dioxin-5-yl-methyl)carbamoyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzyl)carbamate 

Relevant academic research and scientific papers

Arylalkylamine vanadium (V) salts for the treatment and/or prevention of Diabetes mellitus

This invention provides compounds of formula (IIA) and pharmaceutical compositions thereof, where M, a, b, and R1-R5 are as defined herein, for treating human type 1 and type 2 diabetes, particularly insulin-resistant diabetes. Pharmaceutical compositions comprising the compounds of formula (IIA) are also disclosed.

Substituted oxygenated heterocycles and thio-analogues: Synthesis and biological evaluation as melatonin ligands

A new series of substituted oxygenated heterocycles and thio-analogues were synthesized and evaluated as melatonin receptor ligands. The replacement of the indolic moiety of melatonin by heterocyclic skeleton such as 1,4- benzodioxin, 2,3-dihydro-1,4-benzodioxin, chroman, 2,3-dihydro-1,4- benzoxathiin, thiochroman, carrying the amidic chain on the aromatic ring, leads to compounds showing a weak affinity for melatonin receptors, except for the compounds 1cb and 1hb. (C) 2000 Elsevier Science Ltd.